Corcept Therapeutics Inc
CORT· Nasdaq
Released Jul 29, 2026, after the close
10-Q filed Jul 29, 2026, 29 days after period end · 0001628280-26-050613
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $256.15M | $194.43M | $163.80M | $117.72M |
| Net Income | $42.99M | $35.15M | $35.49M | $27.53M |
| EPS Diluted |
Corcept Therapeutics Inc · CIK 1088856 · Engraved from SEC EDGAR
| $0.36 |
| $0.29 |
| $0.32 |
| $0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.